Workflow
ETF午评:创新药ETF天弘领涨4.56%,180治理ETF领跌2.77%
news flash·2025-07-29 03:34

Market Overview - The A-share market showed narrow fluctuations with the Shanghai Composite Index down 0.08%, Shenzhen Component down 0.04%, and the ChiNext Index up 0.92% as of midday [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1,145.9 billion yuan, an increase of 7.1 billion yuan compared to the previous day [1] - Over 3,800 stocks declined across the two markets [1] Sector Performance - The CRO, PET copper foil, and semiconductor sectors experienced gains, while glyphosate and insurance sectors saw adjustments [1] ETF Performance - The Tianhong Innovative Drug ETF (517380) led the gains with an increase of 4.56%, followed by the Guotai Innovative Drug ETF (517110) with a 4.26% rise, and the Hong Kong Stock Connect Innovative Drug ETF (520880) up 3.90% [2] - Other notable ETFs included the Hong Kong Stock Connect Innovative Drug ETF (159570) up 3.87% and the Huatai Innovative Drug ETF (517120) up 3.85% [2] Company Highlights - WuXi AppTec (药明康德) reported a revenue of 20.799 billion yuan for the first half of 2025, a year-on-year increase of 20.64%, with net profit attributable to shareholders reaching 8.56 billion yuan, up 101.92% [2] - The company announced a mid-term dividend plan totaling approximately 1 billion yuan, proposing a cash dividend of 3.5 yuan per 10 shares [2] - WuXi AppTec's CEO, Li Ge, stated that the company achieved strong double-digit growth in revenue and profit for the second quarter, reflecting the unique advantages of its CRDMO business model [3] - The company has raised its full-year revenue target for 2025 and adjusted its free cash flow target accordingly [3]